trending Market Intelligence /marketintelligence/en/news-insights/trending/VEZPH61u_qOKWHh7y36u3Q2 content esgSubNav
In This List

Nemaura Medical closes $2M units offering to fund glucose monitor study

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Nemaura Medical closes $2M units offering to fund glucose monitor study

Nemaura Medical Inc. closed its offering of 1,942,061 units for gross proceeds of about $2 million.

Each unit consisted of a common share and a five-year common share purchase warrant exercisable at $1.04 per share. The units were priced at $1.04 apiece.

The company plans to use the proceeds for a U.S. Food and Drug Administration clinical trial of its noninvasive glucose monitor sugarBEAT. Proceeds will also be used to launch the product in Europe and to develop a second generation of sugarBEAT.

Dawson James Securities Inc. acted as the sole placement agent for the offering.

Loughborough, U.K.-based Nemaura is a medical technology company that develops specialty medical devices.